Kornimate/medical-research-clean huggingface dataset:
implementation of therapy together with early childhood intervention

Conditions: Unilateral Cerebral Palsy

Summary: the purpose of this project is to conduct a pilot hybrid type two implementation and efficacy study on therapy together with early childhood intervention using an explanatory mixed methods approach to evaluate the efficacy and implementation of therapy together. therapy together is a parent led intensive pediatric constraint induced movement therapy (p-cimt) program for young children (3 months-2 years 11 months) with unilateral cerebral palsy (ucp). the research team developed the therapy together program due to the lack of clinical uptake in use of cimt with children with ucp, even though there is consistent and robust evidence that demonstrates a positive treatment effect with the intervention. therapy together is based on the evidence and active ingredients of p-cimt with a primary focus on utility and translation of research to clinical practice.

the long-term research goal is to implement therapy together, a caregiver-led pediatric constraint induced movement therapy program we developed for infants and toddlers with unilateral cerebral palsy, within regular health care models globally. the objective of this proposal is to conduct a pilot study to evaluate the efficacy and implementation of the therapy together program within the state of texas early childhood intervention program by conducting a mixed method, hybrid type two implementation and efficacy study guided by the re-aim framework focusing on reach, effectiveness, adoption, and implementation. the central hypothesis is that therapy together can be successfully implemented within the early intervention model resulting in clinically significant improvements in hand function, occupational performance, and development. the rationale for this hypothesis is that therapy together is an adapted version of an evidence-based intervention specifically developed for implementation within standard of care practice.

Eligibility criteria:
inclusion criteria: * participants were children three months to two years and eleven months old who presented with asymmetric hand use with risk of developing cerebral palsy (cp) or have already been diagnosed with cp that present with unilateral upper limb impairment. inclusion criteria were children who visually attended to objects, showed interest in them, and tried to reach for or grasp objects with their impaired upper extremity were included in the study. exclusion criteria: * exclusion criteria were children with uncontrolled epilepsy, significant visual impairment, severe behavior problems or unable to complete assessment protocol were not included in the study.

Keywords: constraint induced movement therapy pediatric constraint induced movement therapy early childhood intervention therapy together
evaluate efficacy of respiratory rehabilitation personalized mobile services for respiratory diseases

Conditions: Respiratory Disease; Lung Cancer; COPD

Summary: this trial is multicenter prospective study to evaluate clinical efficacy of respiratory rehabilitation personalized mobile services for respiratory disease.

patients with lung cancer or copd who need respiratory rehabilitation were enrolled in this trial. the subjets were randomized to 3 group(a: fixed respiratory rehabilitation program group, b: mixed respiratory rehabilitation program group(fixed respiratory rehabilitation for 6 weeks, and then responsive respiratory rehabilitation for 6 weeks) and c: control group(ordinary rehabilitation service of the site)). patients in group a\&b were provided with mobile application and wearable o2 saturation machine and mobile application monitors physical activity and provides 1. how to do stretching, weight training with the-ra band 2. daily and weekly target of exercise 3. alarm algorithms depending on patient's respiratory status(purse rate and o2 saturation)

Eligibility criteria:
inclusion criteria: * patients with lung cancer or copd * patients with fev1\<80% or fvc\<80% in pulmonary function test * in case of copd, post-bronchodilator fev1 or fvc will be used. * exceptionally lung cancer patients with operation, fev1\>80% or fvc\>80% will be permitted * the distance walked for 6 minutes in 6-minute walk test ≥ 150 m * patients with android phone * patients who voluntarily agree to study participation and provide written informed consent form exclusion criteria: * patients with diseases which could be cause of death or significant disability for 1 year after study enrollment. * patients with diseases that are difficult to walk or improve walking at screening * patients with significant diseases which are difficult to include in this study in accordance with the investigator's judgment * patients who are illiterate or have communication limitations * patients who have a difficulty to complete a questionnaire or are uncooperative due to deterioration of recognition function

Keywords: respiratory rehabilitation personalized mobile services
the effect of oxytocin on face perception

Conditions: Healthy; Congenital Prosopagnosia

Summary: the purpose of this study is to determine whether oxytocin affect face perception


Eligibility criteria:
inclusion criteria: * normal or corrected to normal vision exclusion criteria: * minors * pregnancy (according to a pregnancy test taken by subjects prior to participation) * a history of asthma or nasal polyps * cardiac disorders * hyponatremia * acute or chronic renal insufficiency * liver cirrhosis * neurological disease * other chronic disease * dementia, or lack of judgment

Keywords: oxytocin face memory
diabetic retinopathy and sickle trait

Conditions: Diabetic Retinopathy; Sickle Cell Trait

Summary: to more clearly ascertain the relationship between ocular manifestations of sickle cell disease and diabetes, specifically; whether the presence of sickle cell trait exacerbates the disease progression of diabetic retinopathy.

the objective of this research study is to evaluate the relationship between sickle cell trait and the progression of diabetic retinopathy. people with diabetes have high blood sugar that damages small blood vessels. damage to the blood vessels that supply the retina in the back of the eye is called diabetic retinopathy. diabetic retinopathy is worse in african-americans with diabetes, with earlier and more severe disease progression and common complications including vitreous hemorrhage - where these blood vessels in the eye leak - and retinal detachment - the separation of the nerves of the retina from the back of the eye which may lead to blindness. one explanation for this increased severity of diabetes in african-americans is the presence of sickle cell disease, or even just sickle trait, which causes damage to red blood cells and blood vessels under conditions of stress; like low oxygen levels, or hyperglycemic acidosis.

Eligibility criteria:
inclusion criteria: * self-identified african-american patients with diabetes will be identified from dr bowie's retina clinic at storm eye institute. * these subjects are either being screened or treated for the progression of diabetic retinopathy. exclusion criteria: * none

Keywords: diabetic retinopathy sickle cell trait vision loss eye disease
genetic study of chronic prostatitis/chronic pelvic pain syndrome (cp/cpps)

Conditions: Chronic Prostatitis (CP); Chronic Pelvic Pain Syndrome (CPPS); Painful Bladder Syndrome (PBS); Benign Frequency Syndrome (BFS); Interstitial Cystitis

Summary: chronic prostatitis/chronic pelvic pain syndrome (cp/cpps) is a condition with several causes of which some remain unknown. it is believed that some types of cp may be genetic or passed down (inherited) from one generation to the next. in this study, we are collecting genetic material and medical information to try to determine if genetic factors play a role in cp/cpps. we will be collecting dna (from blood/saliva sample) and urine from each participant. bladder tissue from affected individuals will also be collected. individuals and families with cp/cpps will be enrolled. family members of an individual with cp/cpps are eligible whether or not they also experience cp/cpps symptoms.

we would like to determine if chronic prostatitis/chronic pelvic pain syndrome (cp/cpps) has a genetic cause. we will be attempting to further describe the symptoms of cp/cpps and to correlate them with changes in your genes. we will use several types of genetic testing; linkage analysis, whole exome sequencing and candidate gene studies. each individual participant will be required to give a dna sample (via blood/saliva), a urine sample and answer questionnaires. affected participants will also be asked to provide a bladder sample from a clinical biopsy. all samples will be stored. travel to boston not required.

Eligibility criteria:
inclusion criteria: * have symptoms for at least 3 months within the preceding 6 months: * pain in the pelvic area * urinary frequency and/or * urinary urgency and/or * sexual dysfunction (erectile dysfunction) * have cp/cpps, interstitial cystitis (ic), bladder pain syndrome bps, or bladder fasciculation syndrome (bfs) * be willing to provide a blood/saliva, bladder tissue (from previous biopsy) and urine sample * agree to complete several brief questionnaires * family member of someone with cp/cpps, bps, ic or bfs * live in the usa or canada exclusion criteria: * major structural/anatomical urinary tract abnormalities * underlying inborn or congenital conditions which affect the urinary tract * surgery/chemotherapy in the pelvic area * bacterial cause to cp/cpps or recurrent urinary tract infections (uti) * traumatic cause to cp/cpps

Keywords: urgency frequency pelvic pain sexual dysfunction erectile dysfunction painful intercourse
autologous bmnc infusion for liver cirrhosis in children with ba

Conditions: Biliary Atresia

Summary: to evaluate the safety and early outcomes of autologous bone marrow mononuclear cell (bmmnc) infusion for liver cirrhosis due to biliary atresia (ba) after kasai operation. an open-label clinical trial was performed from january 2015 to december 2021. 12 children with liver cirrhosis due to ba at the time of kasai or after kasai were included. bone marrow was harvested through anterior iliac crest puncture under general anesthesia. mononuclear cells (mncs) were isolated by ficoll gradient centrifugation and then infused into the hepatic artery.

biliary atresia (ba) is a progressive fibro-obliterative cholangiopathy and a fatal disease. without surgery, children with ba rarely survive beyond three years of age. the reported prevalence of ba ranges from 1 in 9640 to 1 in 19,500 live births. in the past, most children with a "non-correctable" type of ba died without adequate treatment. recently, stem cell administration has been applied in adults with liver cirrhosis and has shown promising outcomes. an open-label clinical trial was performed from january 2015 to december 2021. 12 children with liver cirrhosis due to ba at the time of kasai or after kasai were included. bone marrow was harvested through anterior iliac crest puncture under general anesthesia. mononuclear cells (mncs) were isolated by ficoll gradient centrifugation and then infused into the hepatic artery. serum bilirubin, albumin, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, and prothrombin time were monitored at baseline, three months, six months and 12 months after the transplantation. esophagoscopies and liver biopsies were performed in patients whose parents provided consent. this study aimed to evaluate both safety and hepatic function after bmmnc administration in these children.

Eligibility criteria:
inclusion criteria: * children were diagnosed with liver cirrhosis due to biliary atresia after kasai's operation * two months old or older * patients with a manifestation of cirrhosis after kasai's operation: hepatomegaly, congestive splenomegaly, elevated liver enzymes, esophageal varices (based on endoscopic diagnosis), cirrhosis (based on liver biopsy) exclusion criteria: * epilepsy * coagulation disorders * allergy to anesthetic agents * severe health conditions such as cancer, failure of heart, lung, liver or kidney * active infections * severe psychiatric disorders
a research study looking at how 50 mg semaglutide daily affects food intake and emptying of the stomach in people with obesity

Conditions: Obesity

Summary: this study tests if semaglutide tablets of 50 mg can help people with obesity to lower their food intake compared to placebo. this study also tests how semaglutide 50 mg works on appetite, control of eating (such as cravings and restraints) and how long time the food stays in the stomach after a meal. in addition, how much semaglutide is in the blood will also be tested. participants will either get semaglutide or placebo - which treatment participants will get is decided by chance. participants will receive one semaglutide (or placebo) tablet per day during the 20-week treatment period. the dose of semaglutide is slowly increased every 4 weeks during the study to reach the treatment dose of 50 mg semaglutide taken for 4 weeks. the study lasts for up to 29 weeks for each person and includes a screening period (up to 4 weeks), a treatment period (20 weeks) and a follow-up period (total of 5 weeks after the last dosing). participants will have 12 visits with the study doctors at the institute.


Eligibility criteria:
inclusion criteria: * male or female, aged 18-65 years (both inclusive) at the time of signing informed consent * body mass index between 30.0 and 45.0 kilogram per meter square (kg/m\^2) (both inclusive) exclusion criteria: * female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method * any disorder which in the investigator's opinion might jeopardise participant safety or compliance with the protocol * presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal, or endocrinological conditions
a study of patients with lower extremity acute limb ischemia to remove thrombus with the indigo™ aspiration system (stride ii)

Conditions: Lower Extremity Acute Limb Ischemia; LE ALI

Summary: the primary objective of this study is to collect and evaluate clinical evidence supporting the safety and performance of the indigo™ aspiration system in a patient population with lower extremity acute limb ischemia (le ali).


Eligibility criteria:
inclusion criteria: * age ≥18 years * patients with a confirmed diagnosis of lower limb arterial occlusion located in the common iliac or below, with a minimum of 2 cm of proximal patency in the common iliac * acute occlusion with symptom duration of 14 days or less at presentation * ali rutherford category i, iia or iib * first-line treatment with the indigo aspiration system using computer assisted vacuum thrombectomy (cavt) aspiration tubing * informed consent is obtained from either patient or legally authorized representative (lar) per institutional review board/ethics committee requirements * previously enrolled patients presenting with a new acute occlusion in the contralateral limb meeting all eligibility criteria may be re-enrolled if the new acute occlusion is greater than 30 days from the initial index procedure exclusion criteria: * life expectancy \<1 year * target vessel size \<2 mm * target thrombus is in the aorta or isolated profunda artery * prior major amputation (proximal to the tarsometatarsal joint) in the target limb * prior minor amputation in the target limb within the past 6 months that is not completely healed or cannot bear weight * le ali secondary to dissection, vasculitis, or target vessel trauma, including iatrogenic etiology from treatment of a proximal location in the target limb * target thrombus in a saphenous vein bypass graft * treatment of the index event with thrombolytics or any other endovascular or open surgical method prior to enrollment * pregnancy * contraindication or sensitivity to iodinated intravascular contrast that cannot be adequately premedicated * other medical, behavioral, or psychological conditions that, in the opinion of the investigator, precludes the patient from appropriate consent, could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study * current participation in another investigational drug or device study that may confound the results of this study. studies requiring extended follow-up for products that were investigational but have since become
effect of omega-3 fatty acid on cortical function in adhd

Conditions: Attention Deficit Disorder

Summary: the study hypothesis is that dha is more effective than placebo in increasing brain activation and reducing symptoms in psychostimulant-free children with adhd.

this study aims to determine the effects of 10-week dietary supplementation with the long-chain omega-3 fatty acid docosahexaenoic acid (dha) or placebo on prefrontal cortical structural and functional connectivity using several neuroimaging techniques: dti (diffusion tensor imaging), 1h mrs(proton magnetic resonance spectroscopy), and fmri (functional magnetic resonance imaging) in psychostimulant-free children with attention deficit hyperactivity disorder (adhd). it is postulated that dha supplements will increase brain activation and reduce adhd symptomatology.

Eligibility criteria:
inclusion criteria: * provision of written informed consent/assent * ages 5-15 years old * meets dsm-iv-tr criteria for adhd as determined by the ksads exclusion criteria: * contraindication to an mri scan (i.e., braces, claustrophobia) * a history of a major medical (e.g., diabetes) or neurological illness (e.g., epilepsy) * greater than 1 year outside appropriate age/grade level * a history of intolerance or hypersensitivity to omega-3 fatty acids * currently taking omega-3 supplements * not proficient in english language * any history of a hematological disorder or concomitant use of anticoagulant medications * personal history of an axis i psychiatric disorder other than adhd * inability to swallow capsules

Keywords: adhd
efficacy and safety of ibuprofen in patients with ankle injuries

Conditions: Pain

Summary: the objective of the study is to evaluate the efficacy and safety of ibuprofen in patients with ankle injuries.

the objective of the study is to evaluate the efficacy and safety of ibuprofen versus placebo in patients for the treatment of pain related to uncomplicated ankle injuries.

Eligibility criteria:
inclusion criteria: 1. written informed consent obtained. 2. male and female patients, age in the range of 18-45 years (inclusive). 3. patients with pain related to uncomplicated ankle injuries (in case of doubt whether it is complicated an x-ray should be taken). 4. pain related to ankle injuries is scored as moderate or severe by the patient and the injury is less than 24 hours old. 5. patients with normal or clinically non-significant findings as determined by baseline history, physical examination and vital signs (blood pressure, heart rate and axillary temperature). 6. comprehension of the nature and purpose of the study and compliance with the protocol requirements. 7. negative urine pregnancy test (for females only). exclusion criteria: 1. known hypersensitivity to aspirin or any non-steroidal anti-inflammatory drugs (nsaid). 2. known history of asthma. 3. known history of gastric or peptic ulcer or bleeding. 4. known history of malignancy or other serious diseases. 5. known history of skin allergy. 6. known history of cardiac, renal or hepatic insufficiency. 7. presence of bruises or rash on the skin of ankle. 8. presence of skin lesions like eczema or psoriasis. 9. arthritis in the same joint. 10. alcohol use during the study period or within 48 hours before the study enrolment. 11. patients judged unable to use the vas for pain reliably 12. locally applied nsaid to the painful region/area of study or oral use of nsaid or other analgesics 48 hours before the study enrolment. 13. other pain killers than rescue medication to be taken during the study. 14. recurrent sprain at the same joint during the last 6 months. 15. anticoagulant therapy. 16. physiotherapy during study period. 17. open wounds, infected skin or fracture. 18. any other condition that in the opinion of the investigator would interfere with the evaluation of the results or constitute a health risk for the patient. 19. pregnant or lactating females. 20. participation in a drug or device study within 90 days before the study enrolment.
genetics education: preparing physicians for the future

Conditions: Primary Care Genetics; Hereditary Colorectal Cancer

Summary: this study examines the best way to teach genetics to family medicine residents. first year family medicine residents at the university of toronto will be taught basic clinical genetics as well as a specific disease in genetics via 3 different educational methods. all participants will undergo an oral examination and written knowledge test 3 months after this education. results between groups will be compared, and the best way to teach genetics to residents determined.

an educational module will be prepared by the investigators outlining important genetic fundamentals and hereditary colorectal cancer. sixty four family medicine resident participants will take part in this study. participants will be divided into 4 groups. group 1 will be the control and receive no education. group 2 will be given access to the self-study web-based educational module to do on their own time. group 3 will be given a lecture on the material using the educational module, followed by a discussion. group 4 will also be given this lecture and discussion, followed by an interactive standardized patient role-play experience. three months later, all participants will complete an simulated oral examination, an written knowledge test and an attitude survey. by comparing the results between the 4 groups, the best way to teach genetics will be determined. this template can then be used to develop a curriculum for teaching clinical genetics to family medicine residents.

Eligibility criteria:
inclusion criteria: * all first year family medicine residents in the department of family and community medicine at the university of toronto exclusion criteria: -
randomized study comparing mr-guided in bore versus mri/us fusion-guided prostate biopsy

Conditions: Prostate Cancer

Summary: the hypothesis of the study is that targeted mri/us fusion-guided prostate biopsy with additional systematic transrectal ultrasound (trus)-guided biopsy significantly detects more prostate cancers than targeted mr-guided in-bore prostate.

in men with previously negative prostate biopsy and persistent elevated prostate-specific antigen (psa) value, it is unclear which strategy offers the highest detection rate for prostate cancer. the hypothesis of this study is that targeted mri-guided biopsy combined with transrectal ultrasound (trus)-guided biopsy may potentially detect more cancers than mri-guided prostate biopsies alone. men with at least one previously negative trus-guided biopsy and persistently elevated psa values will be submitted to a multiparametric mri examination of the prostate. subsequently, all participants will be randomized (1:1) into both study arms. in study arm a patients will be submitted to targeted prostate biopsy based on the multiparametric mri findings. targeted biopsies will be performed using mri-guided in-bore prostate biopsy. in study arm b targeted biopsies will be performed using mri/trus-fusion-guided prostate biopsy with software-registration (mri/trus image fusion). patients of study arm b undergo additional systematic 12-core trus-guided prostate biopsy.

Eligibility criteria:
inclusion criteria: * at least one prior negative prostate biopsy * prostate-specific antigen (psa) \> 4 ng/ml exclusion criteria: * known prostate cancer * contraindications against mri * contraindications against prostate biopsy

Keywords: mri/us fusion-guided prostate biopsy mr-guided in-bore prostate biopsy prostate cancer